EyeGate Pharmaceuticals, Inc. – NASDAQ:EYEG
EyeGate Pharmaceuticals stock price today
EyeGate Pharmaceuticals stock price monthly change
EyeGate Pharmaceuticals stock price quarterly change
EyeGate Pharmaceuticals stock price yearly change
EyeGate Pharmaceuticals key metrics
Market Cap | 25.34M |
Enterprise value | 19.87M |
P/E | -26.51 |
EV/Sales | 993.85 |
EV/EBITDA | -3.23 |
Price/Sales | 1272.07 |
Price/Book | 4.97 |
PEG ratio | -2.54 |
EPS | -1.67 |
Revenue | N/A |
EBITDA | -10.38M |
Income | -10.43M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -28174.86% |
Oper. margin | -30735.62% |
Gross margin | 100% |
EBIT margin | -30735.62% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEyeGate Pharmaceuticals stock price history
EyeGate Pharmaceuticals stock forecast
EyeGate Pharmaceuticals financial statements
| Dec 2020 | 12.05K | -2.41M | -20032.88% |
|---|---|---|---|
| Mar 2021 | 0 | -2.58M | |
| Jun 2021 | 0 | -2.46M | |
| Sep 2021 | 0 | -2.96M |
| 2021-03-25 | -0.44 | -0.52 |
|---|---|---|
| 2021-05-12 | -0.38 | -0.37 |
| 2021-08-12 | -0.42 | -0.35 |
| Dec 2020 | 15157559 | 8.15M | 53.82% |
|---|---|---|---|
| Mar 2021 | 20620602 | 7.93M | 38.48% |
| Jun 2021 | 18100060 | 7.64M | 42.24% |
| Sep 2021 | 25493339 | 8.14M | 31.95% |
| Dec 2020 | -1.70M | -244.43K | 218K |
|---|---|---|---|
| Mar 2021 | -2.57M | -58.11K | 8.03M |
| Jun 2021 | -2.63M | -5.74K | -278.19K |
| Sep 2021 | -2.27M | 0 | 9.75M |
EyeGate Pharmaceuticals alternative data
| Aug 2023 | 14 |
|---|---|
| Sep 2023 | 14 |
| Oct 2023 | 14 |
| Nov 2023 | 14 |
| Dec 2023 | 14 |
| Jan 2024 | 14 |
| Feb 2024 | 14 |
| Mar 2024 | 14 |
| Apr 2024 | 14 |
| May 2024 | 14 |
| Jun 2024 | 14 |
| Jul 2024 | 14 |
EyeGate Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Jan 2021 | 3062202 | 0 |
| Jul 2021 | 0 | 3221326 |
| Aug 2021 | 0 | 192775 |
| Nov 2021 | 17853 | 0 |
| Patent |
|---|
Application Filling date: 23 Mar 2021 Issue date: 30 Sep 2021 |
Application Filling date: 22 Mar 2021 Issue date: 23 Sep 2021 |
Application Filling date: 30 Apr 2020 Issue date: 5 Nov 2020 |
Wednesday, 13 December 2023 | ||
| AllianceBernstein Launches 5 New Active ETFs | etftrends.com | |
Friday, 1 October 2021 | ||
| EYEG Stock Price: Why It Substantially Increased | Pulse2 | |
Wednesday, 29 September 2021 | ||
| 7 Best Penny Stocks to Buy on the Nasdaq for October | InvestorPlace | |
Friday, 24 September 2021 | ||
| Best Penny Stocks to Buy Right Now? 3 to Watch in October | PennyStocks | |
Wednesday, 15 September 2021 | ||
| Penny Stocks For Your Biotech Watch List In September 2021 | PennyStocks | |
Tuesday, 14 September 2021 | ||
| 4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507% | PennyStocks | |
Thursday, 9 September 2021 | ||
| EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | GlobeNewsWire | |
Wednesday, 8 September 2021 | ||
| EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation | GlobeNewsWire | |
Friday, 20 August 2021 | ||
| Top Penny Stocks You Need to Know About Right Now | PennyStocks |
-
What's the price of EyeGate Pharmaceuticals stock today?
One share of EyeGate Pharmaceuticals stock can currently be purchased for approximately $35.69.
-
When is EyeGate Pharmaceuticals's next earnings date?
Unfortunately, EyeGate Pharmaceuticals's (EYEG) next earnings date is currently unknown.
-
Does EyeGate Pharmaceuticals pay dividends?
Yes, EyeGate Pharmaceuticals pays dividends and its trailing 12-month yield is 4.67% with 0% payout ratio. The last EyeGate Pharmaceuticals stock dividend of undefined was paid on 27 Sep 2025.
-
How much money does EyeGate Pharmaceuticals make?
EyeGate Pharmaceuticals has a market capitalization of 25.34M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.55% to 12.06K US dollars. EyeGate Pharmaceuticals made a loss 8.09M US dollars in net income (profit) last year or -$0.35 on an earnings per share basis.
-
What is EyeGate Pharmaceuticals's stock symbol?
EyeGate Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "EYEG".
-
What is EyeGate Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of EyeGate Pharmaceuticals?
Shares of EyeGate Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does EyeGate Pharmaceuticals have?
As Jul 2024, EyeGate Pharmaceuticals employs 14 workers.
-
When EyeGate Pharmaceuticals went public?
EyeGate Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 13 Feb 2015.
-
What is EyeGate Pharmaceuticals's official website?
The official website for EyeGate Pharmaceuticals is eyegatepharma.com.
-
Where are EyeGate Pharmaceuticals's headquarters?
EyeGate Pharmaceuticals is headquartered at 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS.
-
How can i contact EyeGate Pharmaceuticals?
EyeGate Pharmaceuticals's mailing address is 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS and company can be reached via phone at +1 781 788 9043.
EyeGate Pharmaceuticals company profile:
EyeGate Pharmaceuticals, Inc.
eyegatepharma.comNASDAQ
14
Biotechnology
Healthcare
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Waltham, MASSACHUSETTS 02452
CIK: 0001372514
ISIN: US30233M5031
CUSIP: 30233M503
